. >> let's turn to chris otmecons r instance of the high cost of drugs in the u.s.earch analyst at raymond james. thanks for joining us tonight. >> thanks for having me. >> an insuran industry analyst said the other day that if this drug, even if it's effective, it's useless if nobody can afford it. how do you read this situation? >> yeah, i think there's n question that a drug in the pharmacy is no use to expect and when you have babies that pass away without this dr, the upside is very encouraging for what we see, but there has to be a way to find a good balance. i think that most insurers are veryov likely to a drug like this because of the positive impact that grew see, and i think it's really difficult to see novartis from a political standpoint, thenality to pay for the child to die, and we hope a good person, perspective, and the company will step in to be that those that need it most will be able to have access to the drug because they don't want congress and the administration to step in, and to try and lower the price ask interfere in the market market. ye